SNDX

Syndax Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 12:59 UTC

Last close

10.45USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-26

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-02
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-02
The filing itself
-165.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
-187.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-02
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.15 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Follow one dollar

lens 1 of 9

After what it costs to make

n/a

After running the business

-158%

After interest and tax

-166%

After what it must reinvest

-188%

Kept after the dividend

n/a

after running the business, -158.4% of sales; after interest and tax, -165.6% of sales; after what it must reinvest, -187.5% of sales

The five stops

3 of 5 read

After what it costs to maken/an/a
After running the business-273,084,000-158%
After interest and tax-285,422,000-166%
After what it must reinvest-323,167,000-188%
Kept after the dividendn/an/a

The last stop is empty on purpose. This filing does not tag a common dividend, so what is kept after it cannot be worked out. That is not the same fact as a company that paid no dividend, and we will not print a zero for it.

What is left after the dividend is not held for this company.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales172,352,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
After what it costs to maken/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
After running the business-273,084,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
After interest and tax-285,422,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
After what it must reinvest-323,167,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
Kept after the dividendn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself